CMPI

Checkmate Pharmaceuticals Inc.

Price

chg

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

low api

52 wk hi

high api

Cash

$70.9M

Burn Rate (Qtr)

$10.0 M

Mkt Cap

mkt cap api

Avg Volume

volume api

*cash/burn updated:

Q4 '21

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information.

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Vidutolimod (CMP-001)

Cancer, Cutaneous squamous cell carcinoma

Phase 2

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Vidutolimod (CMP-001)

Cancer, Melanoma

Phase 2

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Vidutolimod (CMP-001)

Cancer, Melanoma

Phase 2

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Vidutolimod (CMP-001)

Head and neck cancer, Cancer

Phase 2

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

CMPI

BPIQ_Logo_RGB-01.jpg

Company Profile

CMPI was acquired by REGN on 5/31/2022

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Recent Posts

See what the community is saying - click to see full post.